Primary Hyperlipoproteinemias (Hyperlipidemias) Other Than Familial Hypercholesterolemia
There are various types of primary hyperlipoproteinemias (hyperlipidemias) other than familial hypercholesterolemia (FH). These types are clinically important and classified according to their associated pathophysiology and genetic abnormalities ( Table 1) 1)
. Familial lipoprotein lipase (LPL) deficiency manifests as severe hyperchylomicronemia and may present with eruptive cutaneous xanthomas or acute pancreatitis, although it does not necessarily accompany atherosclerotic cardiovascular disease (CVD). On the other hand, familial type Ⅲ hyperlipoproteinemia and familial combined hyperlipidemia (FCHL) are often associated with CVD; therefore, providing early diagnosis and treatment is mandatory. Patients suspected of having these abnormalities must be investigated for the underlying causes of disease and evaluated for lifestyle and diet improvement, drug therapy and the presence of atherosclerosis. The major clinical types of this condition are described below.
Familial Combined Hyperlipidemia (FCHL) 1) Genetic and Environmental Background
The basic phenotype of FCHL is type Ⅱb hyperlipoproteinemia, although it varies from type Ⅱa to Ⅳ depending on secondary factors, such as dietary effects. This is a genetic hyperlipoproteinemia, and the first degree relatives of affected patients may develop hyperlipoproteinemias of type Ⅱa, Ⅱb or Ⅳ. This condition used to be considered an autosomal dominant disease caused by a single gene mutation; however, more recently, it has been found to be associated with enhanced hepatic apolipoprotein (apo) B-100 synthesis, decreased LPL activity, increased very-low-density lipoprotein (VLDL) secretion from the liver and the accumulation of visceral fat as factors for the development of symptoms and has been reported to be related to abnormalities of the LPL and APOC-Ⅱ genes or APOA-Ⅰ/C-Ⅲ/A-Ⅳ gene cluster. However, none of these findings have been proven to be definitive. It has also been suggested that FCHL is caused by a polygenic background that tends to induce hyperlipoproteinemia due to environmental factors, such as overnutrition and a low level of physical activity. The prevalence of this disease is as high as 1/100 in the general population.
2) Clinical Manifestations
In patients with FCHL, hyperlipoproteinemia appears after puberty, and the increase in the serum LDL-cholesterol (LDL-C) levels is relatively mild compared with that observed in patients with FH. In contrast to FH, Achilles tendon thickening is not observed in patients with FCHL. The frequency of coronary artery disease (CAD) is high, although not as high as that observed in FH patients 2, 3) . In Japan, among patients with FCHL, myocardial infarctions are observed in men ≥ 35 years of age and women ≥ 55 years of age 4) . FCHL is detected in 32% of patients ≤ 65 years of age with myocardial infarctions in Japan 5) , indicating that FCHL is the most common primary hyperlipoproteinemia in CAD patients.
3) Laboratory Findings and Diagnosis
Insulin resistance frequently develops in patients with FCHL, and the synthesis and excessive secretion of VLDL occur due to the increased input of free fatty acids to the liver. As a result, the serum apo B levels Familial type Ⅲ hyperlipoproteinemia, a hereditary type of hyperlipoproteinemia also called broad β disease, is a disease in which remnant lipoproteins, such as intermediate-density lipoprotein (IDL), chylomicron remnants and β-VLDL (cholesterol-rich VLDL that migrates in the β position on electrophoresis), accumulate. Familial type Ⅲ hyperlipoproteinemia is caused by abnormalities in apo E (apo E2/E2 or apo E deficiency). Apo E is an important apolipoprotein in the uptake of IDL and chylomicron remnants by the liver. Variants include wild-type E3 and isoforms E2 and E4. The proportion of the population with the APOE2/E2 genotype is estimated to be approximately 0.2% in Japan, while very few individuals are diagnosed with familial type Ⅲ hyperlipoproteinemia (0.01% to 0.02% of the general population).
Abnormalities in apo E result in the impaired uptake of chylomicron remnants and IDL by the liver, leading to the accumulation of these lipoproteins in the blood. However, in many cases, remarkable hyperlipoproteinemia does not occur in the presence of apo E2/E2 only, as this condition usually develops in association with other abnormalities [e.g., diabetes mellitus (DM), obesity or hypothyroidism]. The reported abnormalities of APOE include the APOE2/E2 genotype in addition to other gene mutations, such as APOE1, abnormal APOE3 and APOE deficiency.
2) Clinical Manifestations
Xanthoma striatum palmare and/or xanthoma are relatively high in affected patients, and the amount of apo B is relatively more excessive than that of LDL-C. LDL becomes small, dense LDL, which is rich in triglycerides (TGs), has a smaller particle size and is easily oxidized and likely to transform macrophages into foam cells, thereby promoting atherosclerosis. Small, dense LDL is diagnosed using polyacrylamide gel (PAG) electrophoresis of lipoproteins. The diagnosis should be made according to the diagnostic criteria of the Research Committee for Primary Hyperlipidemia, Research on Measures against Intractable Diseases established by the Japanese Ministry of Health, Labour and Welfare (Table 2) 6, 7) . It is desirable to determine the presence of hyperlipoproteinemia of mixed phenotypes IIa, IIb and IV using a family survey. If it is difficult to conduct a family survey or the LDL particle size cannot be measured, an apo B/LDL-C ratio of ＞1.0 or the presence of small, dense LDL on PAG electrophoresis should be established. It is also important to rule out FH.
4) Treatment
Treatment for FCHL is similar to that for FH. Lifestyle modification and obesity management achieved via dietary and exercise therapy are most important. Patients with FCHL respond well to dietary therapy, and the effects of drugs are greater than those observed in patients with FH. With respect to drug therapy, statins, fibrates and nicotinic acid derivatives are effective. The presence or absence of CVD, such as CAD, is a prognostic factor. analysis is performed to establish the presence of phenotype Ⅲ. Patient screening can be performed in daily practice using lipoprotein electrophoresis to establish the presence of a broad β pattern and an apo E/TC ratio of ≥ 0.05. In lipoprotein analyses using ultracentrifugation or high-performance liquid chromatography (HPLC), the level of LDL-C does not increase, but instead decreases. Since the amount of cholesterol in the IDL fraction (1.006＜d＜1.019) dramatically increases, the presence of a high cholesterol/TG ratio (≥ 0.42) in the VLDL fraction (d＜1.006) should also be assessed. Next, the existence of any abnormalities in the apo E isoforms should be established according to the apo E phenotype or genotype.
Dietary fat restriction is essential. Patients with familial type Ⅲ hyperlipoproteinemia respond relatively well to lifestyle modification resulting from dietary and exercise therapy; thus, early diagnosis and tuberosum may appear in patients with this disease. Patients with familial type Ⅲ hyperlipoproteinemia are likely to develop premature CVD [e.g., CAD, carotid atherosclerosis, renal arteriosclerosis or peripheral arterial disease (PAD)] and may have renovascular hypertension or intermittent claudication due to PAD. The incidence of CAD in patients with familial type Ⅲ hyperlipoproteinemia is high in both Japan and Western countries 8) .
3) Laboratory Findings and Diagnosis
Both the serum TC and TG levels are raised in this patient population. However, the ranges of these parameters vary from slightly increased in patients with normal TC or TG levels to up to 500 mg/dL or 2,000 mg/dL, respectively. The diagnosis is made based on the diagnostic criteria of the Specific Disease Primary Hyperlipidemia Research Group of the Ministry of Health and Welfare (Table 3) 6, 7) . For patients with both increased TC and TG levels, a lipoprotein 
Diagnosis
The diagnosis is confirmed if all of the above criteria ( (1) to (4)) are met. However, in daily practice, a diagnosis may simply be made if criteria (1) to (3) 
